Logo image
Back
Hyperimmune goat serum (Aimspro®): Hope or hype?
Journal article   Peer reviewed

Hyperimmune goat serum (Aimspro®): Hope or hype?

I. Sutton and A.G. Kermode
Journal of Clinical Neuroscience, Vol.13(10), pp.1037-1038
2006
DOI: https://doi.org/10.1016/j.jocn.2006.07.007
url
Link to Published Version *Subscription may be requiredView

Abstract

In March 2005, newspaper and television reports from the UK suggested that treatment with Aimspro®, a ‘hyperimmune goat serum’ (HGS), resulted in an improvement in symptoms attributed to multiple sclerosis. In September 2005, the Hansard record of UK parliamentary debates noted while at least 250 people with multiple sclerosis had received this product, it was unlicensed and a report by the UK Medicines and Healthcare Regulatory Agency (MHRA), had found ‘critical and major deficiencies concerning good manufacturing practice’. Furthermore, the MHRA had previously requested that product manufacturers, Daval International Ltd, remove misleading claims regarding HGS from its website: to date there is no data regarding mechanism of action or demonstration of clinical efficacy in a placebo-controlled trial that has been published in a peer-reviewed full-length journal article...

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

29 Record Views
3 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.52 Neurodegenerative Diseases
1.52.765 ALS Mechanisms
Web Of Science research areas
Clinical Neurology
Neurosciences
ESI research areas
Neuroscience & Behavior
Logo image